Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, USA.
Cancer Lett. 2010 Oct 28;296(2):168-77. doi: 10.1016/j.canlet.2010.04.005.
Glioblastoma patients have a poor prognosis, even after surgery, radiotherapy, and chemotherapy with temozolomide or 1,3-bis(2-chloroethy)-1-nitrosourea. We developed an in vitro recovery model using neurosphere cultures to analyze the efficacy of chemotherapy treatments, and tested whether glioblastoma neurosphere-initiating cells are resistant. Concentrations of chemotherapy drugs that inhibit neurosphere formation are similar to clinically relevant doses. Some lines underwent a transient cell cycle arrest and a robust recovery of neurosphere formation. These results indicate that glioblastoma neurospheres can regrow after treatment with chemotherapy drugs. This neurosphere recovery assay will facilitate studies of chemo-resistant subpopulations and methods to enhance glioblastoma therapy.
胶质母细胞瘤患者预后不良，即使经过手术、放疗和替莫唑胺或 1,3-双（2-氯乙基）-1-亚硝脲化疗也是如此。我们使用神经球培养物开发了一种体外恢复模型，以分析化疗治疗的效果，并测试胶质母细胞瘤神经球起始细胞是否具有耐药性。抑制神经球形成的化疗药物浓度与临床相关剂量相似。一些细胞系经历了短暂的细胞周期停滞和神经球形成的强烈恢复。这些结果表明，胶质母细胞瘤神经球在化疗药物治疗后可以重新生长。这种神经球恢复测定法将有助于研究化疗耐药亚群和增强胶质母细胞瘤治疗的方法。
